Program
Avapritinib
Also written as “avapritinib” and “CS3007 (BLU-285)”.
Its studies are mostly in Gastrointestinal Stromal Tumors · Mastocytosis, Systemic · Leukemia, Mast-Cell · Central Nervous System Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 92 open or running | phase 4since Mar 29, 2021 | Jul 23, 2015 | Jun 23, 2027phase 2 · NCT03731260 |
| CStone Pharmaceuticals | 10 open or running | phase 2since Dec 9, 2019 | Dec 9, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2015First study: phase 1 study in Gastrointestinal Stromal TumorsNew to SanofiSanofi · NCT02508532 · 250 enrolled · United States, Belgium, France and more
- Sep 15, 2015Phase 1 study in Mastocytosis, SystemicSanofi · NCT02561988 · 86 enrolled · United States, United Kingdom
- Mar 7, 2018Phase 3 study in Gastrointestinal Stromal TumorsSanofi · NCT03465722 · 476 enrolled · United States, Australia, Austria and more
- May 3, 2018Phase 2 study in Mastocytosis, SystemicSanofi · NCT03580655 · 107 enrolled · United States, Austria, Canada and more
- Oct 30, 2018Phase 2 study in Mastocytosis, SystemicSanofi · NCT03731260 · 251 enrolled · United States, Belgium, Canada and more
- Dec 9, 2019CStone Pharmaceuticals's first study: phase 2 study in Gastrointestinal Stromal TumorsNew to CStone PharmaceuticalsCStone Pharmaceuticals · NCT04254939 · 65 enrolled · China
- Feb 9, 2021Phase 2 study in Central Nervous System NeoplasmsSanofi · NCT04773782 · 29 enrolled · United States, Australia, Austria and more
- Mar 29, 2021Phase 4 study in Gastrointestinal Stromal TumorsSanofi · NCT04825574 · 2 enrolled · France
- May 27, 2021Phase 1 study in Gastrointestinal Stromal TumorsSanofi · NCT04908176 · 10 enrolled · United States
- Dec 19, 2024Phase 4 study in Mastocytosis, SystemicSanofi · NCT06748001 · 60 planned · Belgium, Canada, France and more
Ahead
- Jun 23, 2027Primary completion: phase 2 study in Mastocytosis, SystemicSanofi · NCT03731260
- Dec 31, 2027Primary completion: phase 4 study in Mastocytosis, SystemicSanofi · NCT06748001
TargetBeta
“An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06748001Mastocytosis, Systemic · Belgium, Canada, France and more | 4 | Recruiting | Sanofi | Dec 31, 2027 | 60 |
| NCT04908176Gastrointestinal Stromal Tumors · United States | 1 | Completed | Sanofi | Mar 1, 2024 | 10 |
| NCT04825574Gastrointestinal Stromal Tumors · France | 4 | Completed | Sanofi | Nov 23, 2023 | 2 |
| NCT04773782Central Nervous System Neoplasms · United States, Australia, Austria and more | 2 | Completed | Sanofi | Nov 21, 2025 | 29 |
| NCT04254939Gastrointestinal Stromal Tumors · China | 2 | Completed | CStone Pharmaceuticals | Apr 30, 2020 | 65 |
| NCT03731260Mastocytosis, Systemic · United States, Belgium, Canada and more | 2 | Active, not recruiting | Sanofi | Jun 23, 2027 | 251 |
| NCT03580655Mastocytosis, Systemic · United States, Austria, Canada and more | 2 | Completed | Sanofi | Dec 18, 2024 | 107 |
| NCT03465722Gastrointestinal Stromal Tumors · United States, Australia, Austria and more | 3 | Completed | Sanofi | Mar 9, 2020 | 476 |
| NCT02561988Mastocytosis, Systemic · United States, United Kingdom | 1 | Completed | Sanofi | Oct 5, 2022 | 86 |
| NCT02508532Gastrointestinal Stromal Tumors · United States, Belgium, France and more | 1 | Completed | Sanofi | Mar 6, 2020 | 250 |
How it is read
Names in the registry
- “Avapritinib”, 7 entries
- “avapritinib”, 2 entries
- “CS3007 (BLU-285)”, 1 entry
Conditions, from the studies’ own filings
- Gastrointestinal Stromal Tumors, 5 studies
- Mastocytosis, Systemic, 2 studies
- Leukemia, Mast-Cell, 2 studies
- Central Nervous System Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.